A string of complete response letters from the US FDA clouded the 2024 outlook for novel cancer therapies, but a productive pipeline is carrying enough candidates towards second half user fee goal dates to keep oncology the biggest area of approvals yet again for the full year.
Key Takeaways
One-third of novel agents with user fee goals in the rest of the year are intended for cancer patients, keeping oncology in position to remain dominate in 2024 despite five first-half complete response letters.
Five cell and gene therapies constitute CBER’s second half user fee calendar, which precludes another record-breaking year like 2023 – but still on track for a historically high number of novel biologic approvals
While about 20% of first half approvals were in the oncology space, one-third of the upcoming 2024 user fee goal dates are for products targeting cancer patients – primarily treatments, but also imaging and supportive care, the Pink Sheet US FDA Performance Tracker’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?